menu search

OXBDF / Oxford Biomedica ciimbs on French contract manufacturer acquisition

Oxford Biomedica ciimbs on French contract manufacturer acquisition
Oxford Biomedica jumped 10% as it started exclusive negotiations to acquire ABL Europe, a contract manufacturing (CDMO) business, from Institut Mérieux. In a statement, Oxford Bio said the deal, if agreed, would instantly give it a multi viral vector CDMO capabilities across multiple sites in EU, US and UK plus bolster its cell and gene therapy contract services. Read More
Posted: Sep 20 2023, 09:28
Author Name: Proactive Investors
Views: 101992

OXBDF News  

Oxford Biomedica ciimbs on French contract manufacturer acquisition

By Proactive Investors
September 20, 2023

Oxford Biomedica ciimbs on French contract manufacturer acquisition

Oxford Biomedica jumped 10% as it started exclusive negotiations to acquire ABL Europe, a contract manufacturing (CDMO) business, from Institut Mérie more_horizontal

Oxford Biomedica stock soars on rosy forecast, talks to buy ABL Europe

By Reuters
September 20, 2023

Oxford Biomedica stock soars on rosy forecast, talks to buy ABL Europe

Oxford Biomedica's shares jumped as much as 16% on Wednesday after the British cell and gene therapy company said it would break even earlier than exp more_horizontal

Oxford Biomedica signs new deal to make AstraZeneca COVID shot

By Fox Business
July 1, 2022

Oxford Biomedica signs new deal to make AstraZeneca COVID shot

Britain's Oxford Biomedica announced an agreement to potentially make AstraZeneca's COVID-19 vaccine beyond 2022. It has already manufactured more tha more_horizontal

Oxford Biomedica Plc (OXBDF) Interim CEO Dr. Roch Doliveux on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
April 20, 2022

Oxford Biomedica Plc (OXBDF) Interim CEO Dr. Roch Doliveux on Q4 2021 Results - Earnings Call Transcript

Oxford Biomedica Plc ( OTCPK:OXBDF ) Q4 2021 Earnings Conference Call April 20, 2022 8:00 AM ET Company Participants Dr. Roch Doliveux – Chairman, I more_horizontal

Oxford Biomedica, Homology Medicines Enter Deal To Expand Viral Vector Offerings

By Benzinga
January 28, 2022

Oxford Biomedica, Homology Medicines Enter Deal To Expand Viral Vector Offerings

London-listed cell and gene therapy Oxford Biomedica Plc OXBDF said it would form a viral vector manufacturing business with Homology Medicines Inc more_horizontal

Oxford Biomedica, Homology Medicines Enter Deal To Expand Viral Vector Offerings

By Benzinga
January 28, 2022

Oxford Biomedica, Homology Medicines Enter Deal To Expand Viral Vector Offerings

London-listed cell and gene therapy Oxford Biomedica Plc OXBDF said it would form a viral vector manufacturing business with Homology Medicines Inc more_horizontal

Oxford Biomedica, Homology Medicines Enter Deal To Expand Viral Vector Offerings

By Benzinga
January 28, 2022

Oxford Biomedica, Homology Medicines Enter Deal To Expand Viral Vector Offerings

London-listed cell and gene therapy Oxford Biomedica Plc OXBDF said it would form a viral vector manufacturing business with Homology Medicines Inc more_horizontal

Oxford Biomedica in deal with Homology to set up new AAV manufacturing and innovation business

By Proactive Investors
January 28, 2022

Oxford Biomedica in deal with Homology to set up new AAV manufacturing and innovation business

Oxford Biomedica PLC announced an agreement with US company Homology Medicines Inc. to form an adeno-associated virus (AAV)-focused manufacturing and more_horizontal


Search within

Pages Search Results: